Never wanting to put a good cash-producing opportunity to waste, Well Health (TSX: WELL) this morning announced it intends to conduct another financing. The financing comes on the heels of the firm last night reporting Q1 revenues of $126.5 million, and a net loss of $2.3 million.
The financing will see the company conduct a bought deal, lead by Eight Capital and Stifel GMP. The company is looking to raise $30.0 million in gross proceeds, at a price of $3.70 per share. No warrant is being offered under the financing.
Lead orders for the financing are said to come from Li Ka-shing, a Hong Kong based investor, as well as from a larger international sovereign wealth fund. The size of said lead orders was not provided.
An over-allotment option has also been granted in connection with the financing.
Proceeds from the financing are said to be used for growth initiatives, including potential acquisitions of specialty clinics and health opportunities, as well as for working capital and general corporate purposes.
The financing is currently expected to close by May 19.
The company reported a cash position of $36.1 million as of March 31 last night, down from $61.9 million at the start of the quarter. The financing follows a $70 million bought deal offering of convertible debentures completed at the end of November, as well as the announcement of a normal course issuer bid just last month, when the company said it viewed its shares as being undervalued. The company was trading at $4.39 per share at the time.
Well Health last traded at $3.71 on the TSX.
Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
The Grocery Grift: Why Toronto and New York Are About to Light Taxpayer Money on Fire